RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

That's not quite what I said. If the share price were to reach a semi-respectable level--$3 perhaps--based on RD data and some correlated shift in sentiment, it might be tempting for Stoll to raise money--unless he's quite sure he has a deal close to wrapped up. In which he'd wait.

If he is sure that he'll get upfronts before year-end, when an auditor could issue a going concern warning, 'fumes' won't be as critical a condition as it was last time.

NeuroInvestment